TITLE: A systematic review and modelling insights of factors impacting measles vaccine effectiveness

SHORT TITLE: Factors impacting measles vaccine effectiveness

AUTHORS: Samiran Ghosh, PhD[1,*]; Divya Kappara, PhD[2,*]; Nabanita Majumder, PhD[2,*]; Suchita Nath-Sain, PhD[2,*]; Siuli Mukhopadhyay, PhD[1,2]

*Contributed equally to the work

AFFILIATIONS:
[1]Department of Mathematics, Indian Institute of Technology, Bombay, Mumbai-400076, Maharashtra, India
[2]National Disease Modelling Consortium, Indian Institute of Technology, Bombay, Mumbai-400076, Maharashtra, India

SG: Institute postdoctoral fellow, ghosh.samiran987@gmail.com
DK: Postdoctoral Associate, kapparadivya@gmail.com
NM: Senior Research Scientist, 30005801@iitb.ac.in
SNS: Senior Executive Officer, snsain@gmail.com

CORRESPONDING AUTHOR:
Prof. Siuli Mukhopadhyay
Professor
Department of Mathematics, Room - 204E
Indian Institute of Technology Bombay
Mumbai-400076, India
Email: siuli@math.iitb.ac.in
Telephone: 91-22-2576-7495

SYSTEMATIC REVIEW
NUMBER OF TABLES: Main text, 1; Supplementary materials, 4
NUMBER OF FIGURES: 4
FINANCIAL SUPPORT: Funding for this study was provided by the Bill & Melinda Gates Foundation (INV-044445)

AUTHOR'S CONTRIBUTION:
Screened references, drafted and approved final version of the manuscript:
Samiran Ghosh, Divya Kappara, Nabanita Majumder, Suchita Nath-Sain, Siuli Mukhopadhyay
Modelling analysis:
Samiran Ghosh, Divya Kappara, Siuli Mukhopadhyay

TITLE: A systematic review and modelling insights of factors impacting measles vaccine effectiveness

ABSTRACT

Background & objectives

Outbreaks of measles have been frequently reported despite the availability of an effective vaccine. In this systematic review we examine the potential factors that could impact the effectiveness of the measles vaccine (MV) in children.

Methods

We conducted a literature search using PubMed and Google Scholar for primary articles published between 2014 and July 2024. Articles reporting the effectiveness or immunogenicity of MV in children aged 0-15 years were included. Additionally, we use regression analysis on data available from few cohort studies in India and epidemiological modelling simulations to assess the effect of factors on vaccine effectiveness (VE).

Results

Overall, 34 primary articles involving 151888 children who had received the MV were included in the analysis. Key factors that may affect VE were malnutrition, genetic variants, chemotherapy and gender. Through modelling we identified an inverse relationship between malnutrition and measles VE and estimated the possible percentage decrease in VE due to malnutrition across different states of India.

Additionally, simulations from a Susceptible-Infected type model showed the effect of varying VE on the modelling outcomes and measles elimination targets.

Interpretation & conclusions

We identified a few key factors that impact measles VE. Therefore, in addition to maintaining WHO recommended vaccine coverages, addressing the problems related to VE is crucial for achieving measles elimination targets.

Keywords: epidemiological modelling, malnutrition, measles, modelling, systematic review, vaccine effectiveness

INTRODUCTION

Measles is a highly contagious, vaccine-preventable viral disease caused by *Measles morbillivirus,* a member of the Paramyxoviridae family[1]. The virus is transmitted by respiratory droplets, small particle aerosols, and close contact. Each infection can cause 12-18 secondary cases among the at-risk population.

Vaccination against measles at the community level has been the most effective way to prevent the disease[2]. The World Health Organization (WHO) currently recommends administering the first dose of the vaccine at 9 months in areas where measles is common, and at 12-15 months elsewhere. A second dose is recommended, usually at 15-18 months.

Despite the availability of an effective vaccine, measles virus remains an important cause of worldwide mortality and morbidity accounting for 136,000 deaths in 2022[2]. While measles vaccination has prevented ~57 million deaths between 2000-2022, it is still a common disease in many parts of the world with yearly outbreaks. In India particularly, several recent outbreaks have threatened the elimination efforts in the country[3,4], underscoring the need to assess the underlying factors contributing to outbreaks.

Vaccine effectiveness (VE) has been noted to vary in different populations, with lower estimates particularly in African and South East Asian countries. Variation between individuals in the immune response to vaccination for several diseases including measles, have been reported widely in the literature[5-9]. Zimmerman et al[9] reported that an estimated 19 million measles vaccinated children have been left unprotected due to ineffectiveness of the measles vaccine (MV).

In this systematic review, our aim is to identify the important factors, particularly the socio-demographic factors, which may be responsible for lowering the VE of MV in children. Identifying these factors should lead to better preparedness in controlling future measles outbreaks as policymakers can take into account the effect of a lower VE in their disease intervention and elimination measures. Additionally, we assess the effect of a key factor of VE using statistical tools and study the impact of varying VE on epidemiological model predictions through simulations.

METHODS

We conducted a systematic review in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement[10].

Search strategy

We searched PubMed and Google Scholar for primary articles published between 2014 and July 2024 using Medical Subject Headings (MeSH) terminology for our population of interest including infants, preterm infants, premature birth, premature infants, children or adolescents; interventions including measles-mumps-rubella vaccine, MMR vaccine, pluserix, virivac, trimovax, triviraten berna, or priorix; and outcomes including VE, vaccine immunogenicity, or antibody response. The literature search was limited to articles reported in English. Additionally, articles were identified from websites as well as from references cited in review articles.

Inclusion and exclusion criteria

Primary articles reporting the effectiveness or immunogenicity of MV in children aged

0-15 years were included. Narrative or systematic reviews, meta-analysis, book chapters, letters, as well as articles reporting other disease areas or not meeting the inclusion criteria were excluded.

Selection and data extraction

Articles retrieved from the databases were imported to EndNote 21 and duplicates were removed. Two authors independently screened the articles based on titles and abstracts. Relevant data were extracted from the selected articles by two independent authors using a spreadsheet. Study-level information was recorded in the spreadsheet, which included author names, year of publication, study period, study design, setting, sample size, age group, and factors impacting measles VE. Discrepancies regarding inclusion of individual articles were resolved by discussion with a third author.

Assessment of risk of bias

The risk of assessment was conducted by three independent authors using the Joanna Briggs Institute (JBI) Critical Appraisal tool[11] (Supplementary tables I-IV). Bias was assessed at the study, outcome, and result level. The tool has a specific number of questions for each study type (case-control, cohort, cross-sectional and randomised control trials). Each question is assessed by scoring (yes=1), (no=0) and (unclear or not applicable=0). Based on the total score, each study was categorised as high (20-49%), moderate (50-79%) or low (80-100%) risk. Risk of bias was assessed by three authors and discrepancies were resolved by consensus.

RESULTS

Study selection and characteristics

A total of 514 articles were retrieved from databases (PubMed, 334; Google Scholar, 180), of which 11 duplicates were excluded and 503 were screened based on title/abstract (**Figure 1**). Of these, 460 articles were excluded as they were not primary articles or did not meet the prespecified inclusion criteria. The full-text for 1 article was unavailable leaving 42 articles for review. An additional 37 articles were identified from websites and cross-references of which 12 were considered for fulltext review. After full-text review of a total of 54 articles, 20 articles were excluded as they were not primary articles or did not meet the inclusion criteria. Overall, 34 studies were included in the analysis.

A total of 8 studies were conducted in Asia of which 1 were from India (**Table 1**). Most were cohort studies (n=15), followed by randomised controlled trials (RCTs; n=8), cross-sectional (n=6) and case-control studies (n=5). Community (number of studies=17) and hospital-based studies (n=7) were most common. The studies included 151888 children comprising 7329 infants (0-12 months). Several factors were reported to likely influence VE including age (n=8); malnutrition (n=7); comorbidities (n=5); gender, number of doses (n=6); fever, genetic factors (n=2); as well as cold chain management, preterm birth, vaccine strain and toxin (n=1).

Factors influencing VE

1. Malnutrition

Child malnutrition is an important global public health issue with significant implications[12]. The relationship between malnutrition and childhood diseases like

measles is particularly crucial, highlighting the need for measles vaccination for malnourished children[13].

A 2016 study conducted in Southeast Iran found a significantly lower seroconversion rate among malnourished children. The study involved 270 infants aged 12-months with 236 completing both pre- and post-vaccination blood sampling phases. After receiving the measles–mumps–rubella (MMR) vaccine, the seroconversion rate was 91.2% (95% confidence interval [CI]: 86.7-94.5) indicating a protective response against measles. However, stunting (height-for-age z-score <-2) was strongly associated with a lack of seroconversion (odds ratio=5.6; 95%CI: 1.7-18.2)[14]. Similar conclusions were drawn from a study in the Democratic Republic of Congo, which highlighted a strong association between malnourishment and measles cases. This study also looked at the malnourished children suffering from malaria infection. Lower VE was observed in malaria-endemic countries where many children suffer from malnutrition[15]. In Southern Mexico, low anti-measles serologic coverage (59%) was seen to be associated with age, sex, family size, and underweight[16]. Another study in Brazil found poverty and poor nutritional status to be closely associated with vaccine compliance and antibody positivity[17]. A study conducted in Eastern Mumbai slum areas in children with low nutritional status reported that VE was 64% (95%CI: 23-73%) and 70% (95%CI: 28-88%) for two doses among children <5 years and 515 years, respectively[18]. The above findings show a strong inverse relationship between malnutrition and VE.

2. Age at first dose

Several studies examined whether the age of administration of the first dose impacts VE. In a district of Ethiopia, although the vaccination coverage rate was 95%, the

overall measles VE was only 70.9% (95%CI: 65-79%)[19]. Only 45.1% of children received the first dose at 9 months and 35.3% received a second dose after 12 months. A study in China involving 280 infants showed that administering the MMR vaccine at 8 months, provides comparable immunogenicity as vaccination at 12 months[20]. Similarly, in Finland, where the MMR vaccination age was lowered to 12 months, seropositivity rates and IgG antibody concentrations in 187 3-year-old children were similar regardless of whether children were vaccinated at 11-13 months or 17-19 months[21]. In contrast, a retrospective longitudinal cohort study involving 101736 children reported that administering the MMR vaccine at 16-20 months of age was linked to higher VE compared to 12-15 months of age[22]. Additionally, in a retrospective cohort study conducted in Italy, a significant proportion of immunised individuals did not retain protective levels of anti-measles IgG antibodies 10 years later[23]. This proportion was higher among those vaccinated ≤15 months (20%) compared to those vaccinated at 16-23 months (17%) and ≥24 months (10%). In a study conducted in Guinea-Bissau, among 6417 children 77% had protective antibodies by 9 months after the first dose at 4.5 months. After a second dose at 9 months, 97% maintained antibody levels at 24 months. Among children who received MV at 9 months, 99% had antibody levels at 24 months even without a second dose at 18 months[24]. However, a cross-sectional study conducted in Pune, India, involving 600 children showed that despite receiving the MV at 9 months >25% of children became susceptible by 12-15 months[25].

3. Vaccine strains

MVs are live attenuated and derived from various strains, with globally used strains including Edmonston- Zagreb, Schwarz, Moraten, Leningrad-16, Hu-191

(Shanghai191), CAM-70, TD-97[26]. In India, the Edmonston-Zagreb and Schwarz strains are

primarily used[27,28]. The Hu-191 strain in the MMR vaccine achieved a 100% seropositivity rate for measles when the first dose was administered at 8 or 12

months[20], while the Edmonston-Zagreb strain reached up to 97% seropositivity for early vaccination at ≤6 months and 99% for the first dose at 9 months[24]. Mufson et al[29] evaluated the immunogenicity and safety of various MMR vaccine strains like Priorix™ (MMR-RIT) and MMRII. In a study of 1220 healthy children aged 12–15 months, results showed high seroresponse rates for both MMR-RIT (98.3-99.2%) and MMRII (99.6%) strains. Similarly, in an RCT[30] comparable immune responses was observed for the MMR-RIT (Priorix, GSK) and MMR II (M-M-R II, Merck & Co Inc.) vaccines when administered to 4011 children aged 4-6 years as a second dose, either alone or in combination with the DTaP-IPV and varicella vaccines. These findings suggest that the effect on VE is comparable between vaccine strains.

4. Fever

Fever is a common side effect following measles vaccination. Predictably, measles vaccination may induce fever in 5%-15% of vaccine recipients 7-10 days post-vaccination[31,32]. Fever after vaccination may indicate an innate and/or cell-mediated immune response that precedes the humoral response[33].

A study found that the geometric mean titres (GMT) against measles in children without and with fever after MMR vaccination were 2918 (95%CI: 2318-3673) and 4609 (95%CI: 3629-5853), respectively.[34] These results suggest that fever following vaccination is strongly linked to a higher immune response.

5. Cold chain management

Cold-chain management is crucial for maintaining VE, particularly for temperaturesensitive vaccines like MV. While stable between -70°C and -20°C, the MV rapidly loses potency once reconstituted and exposed to higher temperatures, losing about 50% at 20°C in one hour and nearly all at 37°C[19]. Proper cold-chain management requires keeping vaccines at −20°C in national stores and 2-8°C at health facilities,
with usage within 6 hours post-reconstitution[35,36]. Failure to maintain these conditions can reduce VE, increasing the risk of outbreaks in areas with poor infrastructure[19].

6. Number of doses

Two doses of MV are recommended to ensure robust immunity and prevent outbreaks, as not all children develop immunity from the first dose. According to the Centers for Disease Control and Prevention (CDC), a single dose of MV is approximately 93% effective at preventing measles if exposed to the virus, while two doses are approximately 97% effective[37]. An RCT conducted across several European countries examined the long-term effects of 1 and 2 doses of MMRcontaining vaccines administered in the second year of life[38]. The study found that these vaccines induced antibody responses that persisted post-vaccination with high seropositivity rates even a decade later regardless of the vaccine administered and schedule. A cohort study conducted in the Federation of Bosnia and Herzegovina found that the effectiveness of MV was 91.9% (95%CI: 81.4–96.4%) for a single dose and 97.3% (95%CI: 95.5–98.4%) for two doses[39]. Another study in Australia assessed the effectiveness of MV at the population level using national notification data from 2006-2012[40]. Analysing cases of measles in children born after

1996, the study found the estimated effectiveness of MV to be 96.7% (95%CI: 94.5–98.0%) for one dose and 99.7% (95%CI: 99.2–99.9%) for two doses. Overall, VE for ≥1 dose was 98.7% (95%CI: 97.9-99.2%) suggesting that two doses are more effective than one dose of MV.

7. Preterm birth

A prospective study compared the immune response to MV between infants born prematurely and those born at full term[41]. The study included 65 premature infants (birth weight <1500 g) and 56 full-term infants aged 12 months. The results showed that both groups had similar rates of immunity following vaccination (antibody levels: 2.393 vs. 2.412 UI/mL; p=0.970). Overall, the study concluded that humoral responses to measles did not vary among premature and full-term infants.

8. Toxins

A cross-sectional study in the US analysed the link between blood lead levels and antibody responses to measles, mumps, and rubella in 7005 children aged 6-17 years, using data from the 1999-2004 National Health and Nutrition Examination Survey[42]. Children with blood lead levels of 1-5 µg/dL had 11% (95%CI: -16, -5) lower anti-measles antibodies and were twice as likely to be seronegative for measles. This suggests that lead levels even below the CDC's 5 µg/dL action level may impair immune function and VE.

9. Genetic variants

A genome-wide association study was conducted in the USA focusing on measlesspecific neutralising antibodies and IFNγ ELISPOT responses in 2872

subjects.[43] The findings revealed that common single-nucleotide polymorphisms (SNP) in the

CD46 and IFI44L genes are associated with measles-specific humoral immunity. This study underscores the significance of studying the relationship of genetic variants to the inter-individual variation in immune response following live measles vaccination. Furthermore, a cohort study with 764 healthy children aged 11-18 (Caucasian-American, 80.6%; African-American, 11.6%) from Rochester, was conducted to measure the immune response to MV[44]. An association between postvaccination immune responses and genetic polymorphism in the DDX58 gene (rs669260) was detected. Overall, variation in genes may lead to differences in VE.

10. Treatment for comorbidities

Children with acute lymphoblastic leukaemia (ALL) face a risk of infection from viral diseases like measles after completing chemotherapy, which could be mitigated by MMR vaccination. Results of a retrospective cross-sectional study in Saudi Arabia showed that of 57 children who survived ALL, 35 (61.4%) were seropositive, while 22 (38.6%) were seronegative[45]. Notably, children <5 years had higher rates of seronegativity and protection decreased with time since ALL treatment. Booster vaccination resulted in a seroconversion of 57.1%. Similarly, in another study in the USA, among the 262 leukaemia, solid tumour, or brain tumour survivors, 110 (42%) tested negative for anti-measles IgG antibodies, while 152 (58%) tested positive[46]. A study involving 90 patients treated for ALL in Iran showed that seropositivity to measles was achieved if MMR was administered ≥3 months after chemotherapy[47]. Similarly, a study in China analysed clinical data from 110 children who completed chemotherapy and were subsequently revaccinated with the MMR vaccine[48].

Overall, 70 children were seronegative after chemotherapy. The mean measles antibody titres were 254.4±67.46 mIU/mL at baseline and increased to 1471.0±210.0 mIU/mL and 1872.0±262.1 mIU/mL at 1- and 6-months post-vaccination, but decreased to 1710.0±238.6 mIU/mL at 12 months.

In a cohort study, 19 liver transplant recipients were vaccinated based on the seroprotection status and were followed up to 9 years post vaccination[49]. Approximately half of the recipients lost their seroprotection during the follow-up period likely due to biliary atresia, treatment with anti-rejection drugs, or MMR vaccination before transplantation. These studies highlight the need for periodic monitoring of antibody titres in children with immunocompromising conditions and the potential requirement for booster doses to maintain adequate antibody levels.

11. Gender

VE may vary between males and females. A study using samples from Iran's National Measles Laboratory found that the geometric mean anti-measles IgG antibody level was higher in females, at 554.9 mIU/mL, compared to 468.4 mIU/mL in males[50]. Madi et al conducted an age-stratified serological study in Kuwait with 1000 participants divided into two groups: children aged 5-10 years and adolescents aged 11-20 years[51]. Measles seropositivity was high in both groups, at 94.6% (95%CI: 92.6-96.6) for ages 5-10 and 95% (95%CI: 93.1-97.0) for ages 11-20. The study found no significant difference in antibody levels between the age groups. However, females had a higher GMT of 5.5 IU/ml (95%CI: 5.9-5.0) compared to 4.7 IU/ml (95%CI: 5.2-4.3) in males. Similar observation was reported in other studies as well[21,52]. In a study in Finland, boys vaccinated at 11-13 months had lower antibody concentrations compared to girls and increasing the age of vaccination appeared to

improve antibody responses in boys[21]. This indicates that females may have a stronger immune response to the MV than males.

Risk of bias within studies

Risk of bias was low (80-100%) for most of the included studies. Only three cohort studies and one cross-sectional study showed medium risk of bias (50-79%). No other risks were identified and no studies were excluded based on this assessment.

Modelling the impact of malnutrition on VE

As discussed, earlier VE is implicitly influenced by the proportion of malnourished children under 5 years of age. Due to a limitation of data published after 2014, we utilised data before 2014 to explore this relationship. We based our analysis on VE data available for 5 regions in India, namely Kangra (Himachal Pradesh, 2006), Purulia (West Bengal; 2005, 2006), Surat (Gujarat, 2003) and Cuddalore (Tamil Nadu, 2004) from various cohort studies[53-55]. The proportion of severely malnourished children (below -2 SD) of the above states is obtained from the National Family Health Survey (NFHS) 5.

To understand the relationship between malnutrition and VE, we fit a simple linear regression model to the data. In **Figure 2** we present the fit of two linear models that we have implemented along with the 95% CIs. The former corresponds to a standard simple linear regression model and later is a model where the intercept parameter is constrained to not exceed the baseline VE which we considered to be 98%. We observe a decreasing trend in VE with an increase in undernourished percentage in both the model setups, but they vary in terms of magnitude of slope parameter. For Model-1 the estimated coefficients of intercept and slope are (150.866, -2.036) and for the constrained model (Model-2) estimates are (98, -0.6541).

Furthermore, we use the results of Model-2 to estimate a possible decrease in VE due to undernutrition for all Indian states for a given proportion of undernourished children from (NFHS-5). The expected percentage decrease in VE due to malnutrition is calculated by multiplying the observed percentage of undernourished individuals by 0.6541, the slope estimate derived from Model 2. The results thus obtained for all the states and union territories of India are presented in **Figure 3**.

Impact of VE on measles incidence

Although high vaccination coverage is a must, VE also plays a critical role in determining the extent of an epidemic outbreak. We illustrate this using an SI-type epidemic model as described previously[56,57]. The model is described as follows:

$$S_t = B_t + S_{t-1} - I_t \,,$$

$$I_t = \beta_t {I^{\alpha}}_{t-1} S_{t-1} \,,$$

where, β_t is the disease transmission rate which takes into account the seasonality, α is the mixing parameter, S_t and I_t denote the susceptible and infected individuals at time t. B_t is the adjusted birth rate at time t given by:

$$B_t = \widehat{B_t}\,(1 - \epsilon_1 V_1 (1 - V_2) - \epsilon_2 V_1 V_2),$$

where, $\widehat{B_t}$ is the new births at time t, ϵ_1 and ϵ_2 are the VE after the first and second dose of MV, respectively. The coverages of the first and second doses are denoted as V_1 and V_2, respectively. For illustration purposes, the model uses an initial population size of 5×10^5, the estimates of α=0.97, birth rate of 0.015/26 per bi-weekly period and the seasonal measles transmission rate β is taken from previous studies[58,59]. Vaccine coverages are assumed to be constant over time, with (i) high

coverage: 90% for the first dose and 85% for the second dose; (ii) medium coverage: 85% for the first dose and 75% for the second dose.

Some modelling studies assume high average VE in the range of 90-99%[57,60]. However, VE may be significantly lower in certain regions. For instance, in South East Asian regions, the VE is 77%.[18,61] Our analysis compares a baseline scenario without vaccination to two different vaccination scenarios with average VE of 95% and 77%, of two doses respectively. **Figure 4** displays the cases averted over a span of 20 years. The findings indicate that while vaccination significantly reduces cumulative cases compared to the no-vaccination baseline, the effectiveness of the vaccine is also crucial. Specifically, for high coverage, a vaccine with 95% effectiveness can avert approximately 94.54% of cases, whereas a vaccine with 77% effectiveness can avert about 82.00% (green bars, **Figure 4**). Similarly, for medium coverage, a vaccine with 95% effectiveness can avert 91.07% of cases, whereas a vaccine with 77% effectiveness can avert about 77.83% (blue bars, **Figure 4**). This underscores the importance of VE in managing disease outbreaks and achieving global measles elimination targets.

DISCUSSION

This systematic review highlights several factors that may contribute to the ineffectiveness of MV, which could eventually lead to outbreaks of measles reported in various parts of the world. An important factor to be considered in low-and-middleincome countries is malnutrition among children. Several studies reported that malnutrition was associated with low seroconversion rates in children receiving MV[1418]. Similar observations have been reported for other vaccine-preventable

diseases (VPD) such as rotavirus[62] and tetanus[63]. Malnourished children are at a greater risk of infections[64] and contribute to nearly half of the deaths in children <5 years of age globally[65]. In India, the mean prevalence of malnourished children was 7.56% between 2019-2021[66]. Therefore, vaccination strategies in this population need to be considered carefully.

Furthermore, from our model fit, we noted that higher malnutrition could be a potential factor to lower VE. Also, variation in the malnutrition status at the country or state level may cause an associated variation in the VE. The simulation results of the Susceptible-Infected epidemiological model illustrate that not only vaccine coverage but also VE plays a major part in disease transmission and future outbreaks. Modelling scenarios with higher VE may result in a more optimistic/misleading measles incidence scenario compared to lower VE. However, because actual VE may not be high across regions, region-specific VE should be considered to estimate measles incidence more accurately. Overestimating VE could also adversely impact the measles elimination deadlines.

Several other factors also have an effect on VE. Consistent with studies in other VPDs[9], genetics can play a role in determining the immune response to MV[43,44]. The common SNPs in the CD46 and IFI44L genes and the DDX58 gene are associated with MV-specific immunity. Treatment for comorbidities such as cancer was also reported to impact VE. These studies report that chemotherapy resulted in seronegativity in vaccinated children[45,48]. Therefore, booster doses or vaccination after chemotherapy has been recommended. A previous review has outlined the effects of other cancer therapies on vaccination and has provided points to consider for patients receiving vaccination[67]. Consistent with previous findings for other

vaccines[9], several studies included in this analysis report that the immune response to MV is stronger in females than males outlining the role of gender in VE[21,50-52]. In addition to patient-related factors, the storage and distribution of vaccines or coldchain management also impacts measles VE with higher temperatures reducing vaccine potency.

The effect of some factors identified in our analysis including age, vaccine strain, and preterm birth on VE were either inconclusive or did not show an effect. Studies on the impact of age reported conflicting results with some studies suggesting comparable protection for two different age groups[20,21] and different VE for vaccination at 9 months[24,25], while others reported better or long-term VE when infants were vaccinated at 16-24 months versus <15 months[22,23]. Different vaccine strains showed comparable effects on VE. Other studies showed that VE did not vary between children born preterm or full-term. Only limited studies were obtained for other factors such as the effect of toxins and were insufficient to draw a conclusion on their impact on VE.

Our study had few limitations. Due to a limited number of studies and available data as well as heterogeneity among the studies, a meta-analysis was not feasible. Additionally, since very limited published data on VE was available from India, we carried out a regression analysis using data before 2014. The data on VE at the regional level in India and survey data on undernourished children provided a foundation for our analysis. As more data on VE and other potential factors become available, the application of advanced statistical tools will enable a deeper and more precise understanding of how these factors influence VE leading to more informed insights and effective interventions.

In conclusion, understanding the underlying causes of variation in the VE and identifying geographical regions with lower VE is crucial for measles control and elimination. Thus, policymakers while deciding disease control measures and setting elimination targets will need to have a clear understanding of the variation in VE and the factors causing this variation.

FINANCIAL SUPPORT & SPONSORSHIP: Funding for this study was provided by the Bill & Melinda Gates Foundation (INV-044445).

CONFLICTS OF INTEREST: None

REFERENCES

1. Hübschen JM, Gouandjika-Vasilache I, Dina J. Measles. *Lancet.* 2022;399(10325):678-690.
2. Measles fact sheets. World Health Organization. Available at https://www.who.int/news-room/fact-sheets/detail/measles. Accessed August 15, 2024.
3. Suvvari TK, Kandi V, Mohapatra RK, Chopra H, Islam MA, Dhama K. The reemergence of measles is posing an imminent global threat owing to decline in its vaccination rates amid COVID-19 pandemic: a special focus on recent outbreak in India - a call for massive vaccination drive to be enhanced at global level. *Int J Surg.* 2023;109(2):198-200.
4. Vaidyanathan G. Massive measles outbreak threatens India's goal to eliminate disease by 2023. *Nature.* 2022.
5. Finan C, Ota MO, Marchant A, Newport MJ. Natural variation in immune responses to neonatal Mycobacterium bovis Bacillus Calmette-Guerin (BCG) Vaccination in a Cohort of Gambian infants. *PLoS One.* 2008;3(10):e3485.
6. Nair N, Gans H, Lew-Yasukawa L, Long-Wagar AC, Arvin A, Griffin DE. Agedependent differences in IgG isotype and avidity induced by measles vaccine received during the first year of life. *J Infect Dis.* 2007;196(9):1339-1345.
7. Nakaya HI, Hagan T, Duraisingham SS, et al. Systems Analysis of Immunity to Influenza Vaccination across Multiple Years and in Diverse Populations Reveals Shared Molecular Signatures. *Immunity.* 2015;43(6):1186-1198.
8. Ritz N, Mui M, Balloch A, Curtis N. Non-specific effect of Bacille CalmetteGuérin vaccine on the immune response to routine immunisations. *Vaccine.* 2013;31(30):3098-3103.
9. Zimmermann P, Curtis N. Factors That Influence the Immune Response to Vaccination. *Clin Microbiol Rev.* 2019;32(2).
10. Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *BMJ.* 2021;372:n71.
11. Barker TH, Stone JC, Sears K, et al. The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials. *JBI Evidence Synthesis.* 2023;21(3):494-506.
12. Black RE, Victora CG, Walker SP, et al. Maternal and child undernutrition and overweight in low-income and middle-income countries. *The Lancet.* 2013;382(9890):427-451.
13. Griffin DE. Measles virus-induced suppression of immune responses. *Immunol Rev.* 2010;236:176-189.
14. Zahraei SM, Izadi S, Mokhtari-Azad T. Factors affecting the seroconversion rate of 12-month-old babies after the first injection of measles vaccine in the southeast of Iran. *Hum Vaccin Immunother.* 2016;12(12):3118-3124.
15. Doshi RH, Mukadi P, Shidi C, et al. Field evaluation of measles vaccine effectiveness among children in the Democratic Republic of Congo. *Vaccine.* 2015;33(29):3407-3414.
16. Sánchez-Alemán MA, Gutiérrez-Pérez IA, Díaz-Salgado N, et al. Low Seroprevalence of Measles-Specific IgG in Children of Three Ethnic Groups

from Mexico: Influence of Age, Sex, Malnutrition and Family Size. *Vaccines (Basel).* 2021;9(3).
17. Ferreira MS, Cardoso MA, Mazzucchetti L, Sabino EC, Avelino-Silva VI. Factors associated with incomplete vaccination and negative antibody test results for measles, mumps, and hepatitis A among children followed in the MINA-BRAZIL cohort. *Rev Inst Med Trop Sao Paulo.* 2023;65:e16.
18. Yadav RM, Gomare M, Gaikwad A, et al. Interplay of missed opportunity for vaccination and poor response to the vaccine led to measles outbreak in a slum area of Eastern Mumbai, India. *Epidemiol Infect.* 2024;152:e56. 19. Bati MG, Mulleta D, Deresa W, Gurmesa B. Assessment of Factors Associated with Low Measles Vaccine Effectiveness in Honkolo-Wabe District, Ethiopia. 2021.
20. He H, Chen E, Chen H, et al. Similar immunogenicity of measles-mumpsrubella (MMR) vaccine administrated at 8 months versus 12 months age in children. *Vaccine.* 2014;32(31):4001-4005.
21. Kontio M, Palmu AA, Syrjänen RK, et al. Similar Antibody Levels in 3-Year-Old Children Vaccinated Against Measles, Mumps, and Rubella at the Age of 12 Months or 18 Months. *J Infect Dis.* 2016;213(12):2005-2013.
22. Geier DA, Kern JK, Geier MR. Childhood MMR vaccination and the incidence rate of measles infection: a ten year longitudinal cohort study of American children born in the 1990s. *BMC Pediatr.* 2019;19(1):325.
23. Bianchi FP, Stefanizzi P, De Nitto S, Larocca AMV, Germinario C, Tafuri S. Long-term Immunogenicity of Measles Vaccine: An Italian Retrospective Cohort Study. *J Infect Dis.* 2020;221(5):721-728.
24. Martins CL, Benn CS, Andersen A, et al. A randomized trial of a standard dose of Edmonston-Zagreb measles vaccine given at 4.5 months of age: effect on total hospital admissions. *J Infect Dis.* 2014;209(11):1731-1738.
25. Malshe N, Palkar S, Kulkarni R, Lalwani S, Mishra AC, Arankalle V. Early disappearance of maternal anti-measles, mumps, rubella, and varicella antibodies in Indian infants. *Vaccine.* 2019;37(11):1443-1448.
26. World Health Organization. Measles vaccines: WHO position paper – April 2017. Weekly Epidemiological Record. 92(17), 205-227. Available at: https://iris.who.int/bitstream/handle/10665/255149/WER9217.pdf?sequence=1 . Accessed August 8, 2024.
27. Joshi J, Seth A, Aneja S, Singh AK, Aggarwal MK, Gupta N. Rapid onset optic neuritis following measles vaccine in India: Case report. *Vaccine Reports.* 2016;6:86-88.
28. Shah N, Parikh R, Casabona G, Kolhapure S. A new combined vaccine against measles, mumps, rubella and varicella in India. *Indian Pediatrics.* 2017;54(12):1041-1046.
29. Mufson MA, Diaz C, Leonardi M, et al. Safety and Immunogenicity of Human Serum Albumin-Free MMR Vaccine in US Children Aged 12–15 Months. *Journal of the Pediatric Infectious Diseases Society.* 2014;4(4):339-348.
30. Group M-S. … dose of a measles-mumps-rubella vaccine administered to healthy four-to-six-year-old children: a phase III, observer-blind, randomized, safety and immunogenicity …. *Human Vaccines & Immunotherapeutics.* 2019.

31. Klein NP, Lewis E, Fireman B, et al. Safety of Measles-Containing Vaccines in 1-Year-Old Children. *Pediatrics.* 2015;135(2):e321-e329.
32. Safety and immunogenicity of an upper-range release titer measles-mumpsrubella vaccine in children vaccinated at 12 to 15 months of age: a phase III, randomized study. *Human Vaccines & Immunotherapeutics.* 2018;14(12):2921-2931.
33. Griffin DE. The Immune Response in Measles: Virus Control, Clearance and Protective Immunity. *Viruses.* 2016;8(10).
34. Klein NP, Zerbo O, Goddard K, et al. Genetic associations with a fever after measles-containing vaccines. *Hum Vaccin Immunother.* 2021;17(6):17631769.
35. National Vaccine Wastage Assessment (2018). Ministry of Health & Family Welfare, Government of India. Available at https://www.unicef.org/india/media/6686/file/National%20Vaccine%20Wastage%20Assessment.pdf. Accessed August 15, 2024.
36. Dhanorkar, Abhaykumar B., and Govind Pandit Chaudhari. "Effective cold chain management system status for routine immunization in central Maharashtra." Int J Res Rev. 2018;5(1): 220-6.
37. Measles vaccination. Vaccines & Immunizations. CDC. Available at https://www.cdc.gov/vaccines/vpd/measles/index.html. Accessed August 15, 2024.
38. Carryn S, Feyssaguet M, Povey M, Di Paolo E. Long-term immunogenicity of measles, mumps and rubella-containing vaccines in healthy young children: A 10-year follow-up. *Vaccine.* 2019;37(36):5323-5331.
39. Musa S, Topalović B, Ćatić S, Smajlagić Z. Assessment of vaccine effectiveness during measles outbreak in the Federation of Bosnia and Herzegovina, 2014-2015. *Cent Eur J Public Health.* 2018;26(2):79-82.
40. Pillsbury A, Quinn H. An assessment of measles vaccine effectiveness, Australia, 2006-2012. *Western Pac Surveill Response J.* 2015;6(3):43-50.
41. Ferreira CSM, Perin M, Moraes-Pinto MI, et al. Humoral immune response to measles and varicella vaccination in former very low birth weight preterm infants. *Braz J Infect Dis.* 2018;22(1):41-46.
42. Jusko TA, Singh K, Greener EA, et al. Blood Lead Concentrations and Antibody Levels to Measles, Mumps, and Rubella among U.S. Children. *Int J Environ Res Public Health.* 2019;16(17).
43. Haralambieva IH, Ovsyannikova IG, Kennedy RB, et al. Genome-wide associations of CD46 and IFI44L genetic variants with neutralizing antibody response to measles vaccine. *Hum Genet.* 2017;136(4):421-435.
44. Ovsyannikova IG, Salk HM, Larrabee BR, Pankratz VS, Poland GA. Singlenucleotide polymorphism associations in common with immune responses to measles and rubella vaccines. *Immunogenetics.* 2014;66(11):663-669.
45. Fouda AE, Kandil SM, Boujettif F, Salama YS, Fayea NY. Humoral immune response of childhood acute lymphoblastic leukemia survivors against the measles, mumps, and rubella vaccination. *Hematology.* 2018;23(9):590-595.

46. Crom DB, Walters LA, Li Y, et al. Seroprevalence of Measles (Rubeola) Antibodies in Childhood Cancer Survivors. *J Pediatr Hematol Oncol Nurs.* 2024:27527530231221145.
47. Koochakzadeh L, Khosravi MH, Pourakbari B, Hosseinverdi S, Aghamohammadi A, Rezaei N. Assessment of immune response following immunization with DTP/Td and MMR vaccines in children treated for acute lymphoblastic leukemia. *Pediatr Hematol Oncol.* 2014;31(7):656-663.
48. Wang M, Yuan Q, Deng PF, et al. Measles, mumps, and rubella revaccination in children after completion of chemotherapy and hematopoietic stem cell transplantation: a single-center prospective efficacy and safety analysis. *World J Pediatr.* 2023;19(11):1062-1070.
49. Pittet LF, Gualtieri R, Verolet CM, et al. Long-term persistence of seroprotection against measles following measles-mumps-rubella vaccination administered before and after pediatric liver transplantation. *Am J Transplant.* 2024.
50. Ghafoori F, Mokhtari-Azad T, Foroushani AR, Farahmand M, Shadab A, Salimi V. Assessing seropositivity of MMR antibodies in individuals aged 2-22: evaluating routine vaccination effectiveness after the 2003 mass campaign-a study from Iran's National Measles Laboratory. *BMC Infect Dis.* 2024;24(1):696.
51. Madi N, Altawalah H, Alfouzan W, Al-Nakib W, Al-Roumi E, Jeragh A. Assessment of immune status against measles, mumps, and rubella in young Kuwaitis: MMR vaccine efficacy. *J Med Virol.* 2020;92(8):963-970.
52. Tomášková H, Zelená H, Kloudová A, Tomášek I. Serological survey of measles immunity in the Czech Republic, 2013. *Cent Eur J Public Health.* 2018;26(1):22-27.
53. Desai V, Kapadia S, Kumar P, Nirupam S. STUDY OF MEASLES INCIDENCE AND VACCINATION COVERAGE IN SLUMS OF SURAT CITY. *Indian Journal of Community Medicine.* 2003;28(1):10.
54. Mohan A, Murhekar MV, Wairgkar NS, Hutin YJ, Gupte MD. Measles transmission following the tsunami in a population with a high one-dose vaccination coverage, Tamil Nadu, India 2004–2005. *BMC Infectious Diseases.* 2006;6(1):143.
55. Murhekar MV, Hutin YJ, Ramakrishnan R, et al. The Heterogeneity of Measles Epidemiology in India: Implications for Improving Control Measures. *The Journal of Infectious Diseases.* 2011;204(suppl_1):S421-S426.
56. Finkenstädt BF, Grenfell BT. Time Series Modelling of Childhood Diseases: A Dynamical Systems Approach. *Journal of the Royal Statistical Society Series C: Applied Statistics.* 2002;49(2):187-205.
57. Thakkar N, Gilani SSA, Hasan Q, McCarthy KA. Decreasing measles burden by optimizing campaign timing. *Proc Natl Acad Sci U S A.* 2019;116(22):11069-11073.
58. Bjørnstad ON, Finkenstadt BF, Grenfell BT. Dynamics of measles epidemics: scaling noise, determinism, and predictability with the TSIR model. Ecological Monographs. 2002;72(2):185–202.

59. Jandarov R, Haran M, Bjørnstad O, Grenfell B. Emulating a Gravity Model to Infer the Spatiotemporal Dynamics of an Infectious Disease. *Journal of the Royal Statistical Society Series C: Applied Statistics.* 2013;63(3):423-444.
60. Verguet S, Johri M, Morris SK, Gauvreau CL, Jha P, Jit M. Controlling measles using supplemental immunization activities: A mathematical model to inform optimal policy. *Vaccine.* 2015;33(10):1291-1296.
61. Uzicanin A, Zimmerman L. Field effectiveness of live attenuated measlescontaining vaccines: a review of published literature. *J Infect Dis.* 2011;204 Suppl 1:S133-148.
62. Burnett E, Parashar UD, Tate JE. Rotavirus Infection, Illness, and Vaccine Performance in Malnourished Children: A Review of the Literature. *Pediatr Infect Dis J.* 2021;40(10):930-936.
63. Brüssow H, Sidoti J, Dirren H, Freire WB. Effect of malnutrition in Ecuadorian children on titers of serum antibodies to various microbial antigens. *Clinical Diagnostic Laboratory Immunology.* 1995;2(1):62-68.
64. Katona P, Katona-Apte J. The interaction between nutrition and infection. *Clin Infect Dis.* 2008;46(10):1582-1588.
65. Malnutrition, World Health Organization. 2024. Available at: https://www.who.int/news-room/fact-sheets/detail/malnutrition. Accessed August 14, 2024.
66. Ulahannan SK, Wilson A, Chhetri D, Soman B, Prashanth NS. Alarming level of severe acute malnutrition in Indian districts. *BMJ Glob Health.* 2022;7(4).
67. Einarsson J, Wilkinson AN. Vaccination considerations for patients receiving cancer therapy. *Can Fam Physician.* 2022;68(10):751-752.

TABLE

Table 1. Study characteristics of the included articles

Table 1. Study characteristics of the included articles							
Author, year	**Country**	**Study period**	**Study design**	**Study setting**	**Sample size**	**Age group**	**Factors affecting the effectiveness of measles vaccine**
Bati et al, 2021	Ethiopia	2014	Case-control	Community	204	6-59 months	Age at first dose and Cold chain
Carryn et al, 2019	Czech Republic, Greece, Italy, Lithuania, Norway, Poland, Romania, Russian Federation, Slovakia and Sweden	2005-2006	Randomized controlled trial	Community	1887	12-22 months	Number of doses
Doshi et al, 2015	Democratic Republic of Congo	2010–2012	Case-control	Case-Based (CB) measles surveillance system with laboratory confirmation	2379	12-59 months	Malnutrition
Ferreira et al, 2018	Brazil	2007-2010	Cohort study	Clinic	121	12 months	Preterm birth
Ferreira et al, 2023	Brazil	2015-2016	Cohort study	Community	825	2 years	Malnutrition
Fouda et al, 2018	Saudi Arabia	2014-2017	Cross-sectional	Clinic	57	1-18 years	Treatment for comorbidities
Haralambieva et al, 2018	USA	2001-2011	Cohort study	Community	2872	11-40 years	Genetic variants
He at al, 2014	China	NA	Randomized controlled trial	Community	280	8, 12 months	Age at first dose
Jusko et al, 2019	USA	1999–2004	Cross-sectional	Community	7005	6-17 years	Toxins
Klein et al, 2021	USA	2018	Randomized controlled trial	Community	1736	12-15-month	Fever
Kontio et al, 2016	Finland	2013	Cohort study	Clinic	187	11-13, 17–19 months	Age at first dose
Martins et al, 2014	Guinea-Bissau	2003-2007	Randomized controlled trial	Community+Hospital	6417	4.5-36 months	Age at first dose
Martins et al, 2014	Guinea-Bissau	2003-2007	Randomized controlled trial	Community	900	4.5, 9, 18, and 24 months	Age at first dose
Mufson et al, 2015	USA	2009-2010	Randomized controlled trial	Community	1220	12-15 months	Vaccine strains
Pillsbury et al. 2015	Australia	2006-2012	Case-control	National Notifiable Diseases Surveillance System (NNDSS)	3987	1-15 years	Number of doses
Sánchez-Alemán et al, 2021	Mexico	2017	Cross-sectional	Community	416	6 to 13 years	Malnutrition

The MMR-158 Study Group, 2019	USA	NA	Randomized controlled trial	Community	3846	4-6 years	Vaccine strains
Zahraei et al, 2016	Iran	2013	Cohort study	Urban Health Centers	236	12 months	Malnutrition
Zimmermann et al, 2019	Australia	2013-2016	Randomized controlled trial	Community	471	7-13 months	Gender
Ferreira et al	Brazil	2015-2016	Cohort study	Urban Area	1242	0-2 years	Malnutrition

2023							
Dhanorkar et al 2018	India	2018	Cross-sectional study	Rural area	NA	-	Cold chain management
Doshi et al. 2015	Democratic Republic of Congo (DRC).	2010-2012	Case Control Study	Community	2379	12-59 months	Malnutrition
Geier et al 2019	USA	1990-2009	Cohort study	Hospital	101736	120 months	Age at first dose
ZAHRAEI ET AL. 2016	Iran	2013	Cohort study	Urban Health Centers	270	12-12 months 30 days	Malnutrition
Wang et al 2022	China	2017-2019	Cohort study	Hospital	110	0.8-14.4 years	Treatment for comorbidities
Pittet et al. 2024	Switzerland	2013-2022	Cohort study	Hospital	119	3.4-13.4 years	Treatment for comorbidities
Ovsyannikova et al. 2014	USA	2001-2007	Cohort study	Community	764	11-18 years	Genetic variants
Bianchi et al 2020	Italy	2014-2018	Cohort study	Hospital	4563	All age groups	Age at first dose
Madi et al 2020	Kuwait	2017-2018	Cross-sectional study	Hospital	1000	5-20 years	Gender
Crom et al 2024	USA	2019-2022	Cohort study	Hospital	262	11-30 years	Treatment for comorbidities
Tomášková et al. 2018	Czechia	2013	Cross-sectional study	Community	3111	1-64 years	Age at first dose
Ghafoori et al 2024	Iran	2020	Cohort study	Laboratory	290	2-22 years	Gender
Musa et al. 2018	Bosnia and Herzegovina	2014-2015	Cohort study	Community	906	6-15 years	Number of doses
Koochakzadeh et al. 2014	Iran	2007-2008	Case Control Study	Hospital	90	2-16 years	Treatment for comorbidities

FIGURES

Figure 1. PRISMA flow diagram



Figure 2. Model fit and 95% confidence intervals Model-1 standard linear model (left), Model-2 constrained linear model (right)



Figure 3. Spatial distribution of percentage of undernourished children (left), model estimated percentage decrease in VE due to percentage of undernourishment (right)



Figure 4. Percentage of cases averted for different vaccine effectiveness



SUPPLEMENTARY MATERIALS

Supplementary Table I. Quality assessment of case-control studies											Score((%)	Risk
Author name and year	Q1	Q2	Q3	Q4	Q5	Q6	Q7	Q8	Q9	Q10		
Bati et al, 2021	Y	N	Y	Y	Y	Y	Y	Y	Y	Y	90	Low
Pillsbury et al. 2015	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
Doshi et al, 2015	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
hi et al. 2015	Y	Y	Y	Y	Y	N	N	Y	Y	Y	80	Low
Koochakzadeh et al. 2014	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low

Q1. Were the groups comparable other than the presence of disease in cases or the absence of disease in controls?
Q2. Were cases and controls matched appropriately?
Q3. Were the same criteria used for identification of cases and controls?
Q4. Was exposure measured in a standard, valid and reliable way?
Q5. Was exposure measured in the same way for cases and controls?
Q6. Were confounding factors identified?
Q7. Were strategies to deal with confounding factors stated?
Q8. Were outcomes assessed in a standard, valid and reliable way for cases and controls?
Q9. Was the exposure period of interest long enough to be meaningful?
Q10. Was appropriate statistical analysis used?

Supplementary Table II. Quality assessment of randomized controlled trials														Score (%)	Risk
Author name and year	**Q1**	**Q2**	**Q3**	**Q4**	**Q5**	**Q6**	**Q7**	**Q8**	**Q9**	**Q10**	**Q11**	**Q12**	**Q13**		
He at al, 2014	Y	Y	Y	N	N	Y	Y	Y	Y	Y	Y	Y	Y	84	Low
Martins et al, 2014	Y	Y	Y	U	U	Y	Y	Y	Y	Y	Y	Y	Y	84	Low
Martins et al, 2014	Y	Y	Y	U	U	Y	Y	Y	Y	Y	Y	Y	Y	84	Low
Carryn et al, 2019	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
The MMR-158 Study Group, 2019	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
Mufson et al, 2015	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
Zimmermann et al, 2019	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
Klein et al 2021	Y	Y	Y	Y	Y	Y	Y	Y	Y	U	Y	N	Y	84	Low

Question 1: Was true randomization used for assignment of participants to treatment groups?
Question 2: Was allocation to groups concealed?
Question 3: Were treatment groups similar at the baseline?
Question 4: Were participants blind to treatment assignment?
Question 5: Were those delivering the treatment blind to treatment assignment?
Question 6: Were treatment groups treated identically other than the intervention of interest?
Question 7: Were outcome assessors blind to treatment assignment?

Question 8: Were outcomes measured in the same way for treatment groups?
Question 9: Were outcomes measured in a reliable way?
Question 10: Was follow up complete and if not, were differences between groups in terms of their follow up adequately described and analysed?
Question 11: Were participants analysed in the groups to which they were randomized?
Question 12: Was appropriate statistical analysis used?
Question 13: Was the trial design appropriate and any deviations from the standard RCT design (individual randomization, parallel groups) accounted for in the conduct and analysis of the trial?

Supplementary Table III. Quality assessment of cohort studies												**Score (%)**	**Risk**
Author name and year	**Q1**	**Q2**	**Q3**	**Q4**	**Q5**	**Q6**	**Q7**	**Q8**	**Q9**	**Q10**	**Q11**		
Kontio et al, 2016	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
Haralambieva et al, 2018	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
Ferreira et al, 2018	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
Zahraei et al, 2016	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
Ferreira et al, 2023	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
Ferreira et al 2023	U	U	Y	Y	Y	Y	Y	Y	Y	U	Y	73	Medium
Zahraei et al. 2016	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
Bianchi et al 2020	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
Crom et al 2024	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	Y	90	Low
Ghafoori et al 2024	Y	Y	Y	Y	Y	Y	Y	Y	Y	N	Y	90	Low
Musa et al. 2018	Y	Y	Y	N	N	Y	Y	Y	Y	N	Y	73	Medium
Ovsyannikova et al. 2014	Y	Y	Y	Y	Y	Y	Y	U	U	U	Y	73	Medium
Pittet et al. 2024	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low

Wanget al 2023	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
Geier et al 2019	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	Y	100	Low

1. Were the two groups similar and recruited from the same population?
2. Were the exposures measured similarly to assign people to both exposed and unexposed groups?
3. Was the exposure measured in a valid and reliable way?
4. Were confounding factors identified?
5. Were strategies to deal with confounding factors stated?
6. Were the groups/participants free of the outcome at the start of the study (or at the moment of exposure)?
7. Were the outcomes measured in a valid and reliable way?
8. Was the follow up time reported and sufficient to be long enough for outcomes to occur?
9. Was follow up complete, and if not, were the reasons to loss to follow up described and explored?
10. Were strategies to address incomplete follow up utilized?
11. Was appropriate statistical analysis used?

Supplementary Table IV. Quality assessment of cross-sectional studies									**Score (%)**	**Risk**
Author name and year	**Q1**	**Q2**	**Q3**	**Q4**	**Q5**	**Q6**	**Q7**	**Q8**		
Jusko et al, 2019	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
Fouda et al, 2018	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
Sánchez-Alemán et al, 2021	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
Tomášková et al. 2018	Y	Y	Y	Y	Y	Y	Y	Y	100	Low
Madi et al 2020	Y	Y	Y	Y	Y	Y	Y	Y	100	Low

Dhanorkar et al 2018	Y	Y	Y	Y	U	U	Y	N	75	Medium

1. Were the criteria for inclusion in the sample clearly defined?
2. Were the study subjects and the setting described in detail?
3. Was the exposure measured in a valid and reliable way?
4. Were objective, standard criteria used for measurement of the condition?
5. Were confounding factors identified?
6. Were strategies to deal with confounding factors stated?
7. Were the outcomes measured in a valid and reliable way?
8. Was appropriate statistical analysis used?